SCHEMBL6843762

SCHEMBL6843762

Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(O)O)c(=O)n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 3/20 0.76
PDE4D Q08499 1/20 0.76
SLC29A1 Q99808 1/20 0.76
LMNA P02545 5/20 0.62
MTOR P42345 2/20 0.62
THRB P10828 1/20 0.62
MDM2 Q00987 1/20 0.62
NCOA1 Q15788 1/20 0.62
NCOA3 Q9Y6Q9 1/20 0.62
CACNA1F O60840 2/20 0.50
ALB P02768 2/20 0.50
MAPT P10636 2/20 0.50
CACNA1D Q01668 2/20 0.50
CACNA1S Q13698 2/20 0.50
CACNA1C Q13936 2/20 0.50
POLA1 P09884 2/20 0.47
NT5E P21589 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16130206 1.00 PDE3A (0.76) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL547055 0.89 PDE3A (0.74) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL1880453 0.89 PDE3A (0.74) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL18561536 0.88 PDE3A (0.72) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL21006620 0.88 PDE3A (0.72) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL15316783 0.88 PDE3A (0.80) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL12149492 0.88 PDE3A (0.72) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL18537397 0.88 PDE3A (0.72) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL232223 0.88 PDE3A (0.80) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL12151832 0.88 PDE3A (0.72) PDE3APDE4DSLC29A1LMNAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223620-A1 NOVEL PROCESSES FOR THE PRODUCTION OF POLYNUCLEOTIDES INCLUDING OLIGONUCLEOTIDES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-07-10 US disclosed
EP-4504932-A1 NOVEL PROCESSES FOR THE PRODUCTION OF POLYNUCLEOTIDES INCLUDING OLIGONUCLEOTIDES GlaxoSmithKline Intellectual Property Development Ltd (GB) 2025-02-12 EP disclosed
CN-119013398-A Novel method for producing polynucleotides comprising oligonucleotides 葛兰素史密斯克莱知识产权发展有限公司 2024-11-22 CN disclosed
WO-2023194537-A1 NOVEL PROCESSES FOR THE PRODUCTION OF POLYNUCLEOTIDES INCLUDING OLIGONUCLEOTIDES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-12 WO disclosed
US-6762169-B1 IMPROVED TRANSMEMBRANE DELIVERY OF NUCLEOSIDES CONJUGATED TO AN ARYLPROPIONIC ACID LIGAND (IBUPROFEN) WHICH HAS AFFINITY FOR PLASMA PROTEIN ALBUMIN; ANTISENSE THERAPY ISIS PHARMACEUTICALS, INC. 2004-07-13 US disclosed
US-6656730-B1 Attached to an arylpropionic acid that interacts with human serum albumin; acid is ibuprofen, suprofen, ketoprofen, (S)-(+)- pranoprofen, or carprofen. ISIS PHARMACEUTICALS, INC. 2003-12-02 US disclosed
EP-1185305-A1 LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2002-03-13 EP disclosed
WO-2000076554-A1 LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2000-12-21 WO disclosed